BLTE logo

Belite Bio, Inc American Depositary Shares


BLTE: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.


Show BLTE Financials

Consumer Interest
SEC Filings

Recent trades of BLTE by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard

Recently reported changes by institutional investors

Quiver Logo

No Whale Activity for this ticker

Institutional Holdings Dashboard

Quarterly net insider trading by BLTE's directors and management

Quiver Logo

No recent Insider Trading for this ticker

Insider Trading Dashboard

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Methods of treating metabolic diseases with fused bicyclic pyrazoles Jul. 19, 2022
  • Patent Title: Methods of treating rbp4 related diseases with triazolopyridines May. 18, 2021
  • Patent Title: Methods of treating rbp4 related diseases with triazolopyridines Apr. 02, 2019
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard

Number of mentions of BLTE in WallStreetBets Daily Discussion


Recent insights relating to BLTE

CNBC Recommendations

Recent picks made for BLTE stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in BLTE

Corporate Flights

Flights by private jets registered to BLTE